Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further pro
Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
대표청구항▼
1. An isolated antibody, which binds to human TIM3, comprising a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 41, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 122, and a heavy chain CDR3 comprising the amino acid sequence set forth in S
1. An isolated antibody, which binds to human TIM3, comprising a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 41, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 122, and a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 126, and a light chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 64, a light chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66, and a light chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68. 2. The antibody of claim 1, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 364 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 60. 3. The antibody of claim 1, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, and a variant thereof. 4. The antibody of claim 1, comprising an effectorless IgG1 Fc. 5. The antibody of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 349 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 29. 6. The antibody of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 351 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 29. 7. The antibody of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 353 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 29. 8. A composition comprising the antibody of claim 1, and a carrier. 9. The antibody of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 350 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 29. 10. The antibody of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 352 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 29. 11. The antibody of claim 1, comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 354 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 29. 12. A composition comprising the antibody of claim 2, and a carrier. 13. A composition comprising the antibody of claim 5, and a carrier. 14. A composition comprising the antibody of claim 6, and a carrier. 15. A composition comprising the antibody of claim 7, and a carrier. 16. A composition comprising the antibody of claim 9, and a carrier. 17. A composition comprising the antibody of claim 10, and a carrier. 18. A composition comprising the antibody of claim 11, and a carrier. 19. The antibody of claim 2, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, and a variant thereof. 20. The antibody of claim 2, comprising an effectorless IgG1 Fc. 21. A composition comprising the antibody of claim 19, and a carrier. 22. A composition comprising the antibody of claim 20, and a carrier.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (95)
Presta Leonard G. ; Snedecor Bradley R., Altered polypeptides with increased half-life.
Ladner Robert C. (Iamsville MD), Computer based system and method for determining and displaying possible chemical structures for converting double- or m.
Winter Gregory Paul (Cambridge GB3) Duncan Alexander Robert (Wimbledon GBX) Burton Dennis Raymond (Sheffield GB3), DNA encoding antibodies with altered effector functions.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Korman, Alan J.; Selby, Mark J.; Wang, Changyu; Srinivasan, Mohan; Passmore, David B.; Huang, Haichun; Chen, Haibin, Human monoclonal antibodies to programmed death ligand 1 (PD-L1).
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Immunotheraphy using single chain polypeptide binding molecules.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
McCafferty John,GBX ; Pope Anthony Richard,GBX ; Johnson Kevin Stuart,GBX ; Hoogenboom Henricus Renerus Jacobus Mattheus,GBX ; Griffiths Andrew David,GBX ; Jackson Ronald Henry,GBX ; Holliger Kaspar , Methods for producing members of specific binding pairs.
McCafferty John,GBX ; Pope Anthony Richard,GBX ; Johnson Kevin Stuart,GBX ; Hoogenboom Henricus Renerus Jacobus Mattheus,GBX ; Griffiths Andrew David,GBX ; Jackson Ronald Henry,GBX ; Holliger Kaspar , Methods for producing members of specific binding pairs.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Axel Richard (New York NY) Wigler Michael H. (Cold Spring Harbor NY) Silverstein Saul J. (Irvington NY), Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials.
Huston James S. (Newton MA) Charette Marc F. (West Roxbury MA) Cohen Charles M. (Medway MA) Crea Roberto (Boston MA) Keck Peter C. (Millbury MA) Oppermann Hermann (Medway MA) Rueger David C. (West Ro, Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage.
Griffiths Andrew David,GBX ; Hoogenboom Hendricus Renerus Jacobus Mattheus,GBX ; Marks James David ; McCafferty John,GBX ; Winter Gregory Paul,GBX ; Grigg Geoffrey Walter,AUX, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertoires and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self antibodies from antibody segment repertories and displayed on phage.
Griffiths, Andrew David; Hoogenboom, Hendricus Renerus Jacobus Mattheus; Marks, James David; McCafferty, John; Winter, Gregory Paul; Grigg, Geoffrey Walter, Production of anti-self bodies from antibody segment repertories and displayed on phage.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.